This finding is not in line with the common idea that plasma p-tau biomarkers are more closely associated with early markers of AD such as amyloid [1, 6, 9], while tau-PET is more closely associated with downstream markers of disease progression such as cognitive decline and brain atrophy [38], as discussed in the previous paragraph. This evidence concerns the gene MAPT and amyloidosis.